Authorization

Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12

SHANGHAI, China, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of type 2 diabetes, today announced that 24-week topline data of dorzagliatina??s monotherapy trial (HMM0301) will be released on November 12, 2019, and management will present the results and answer any questions via conference call.
Date: November 12, 2019 (Tuesday)Dial in details:

Time:A 



7:30 a?? 8:30 a.m.A  in English (HK Time)







Conference code: 5948512#







8:30 a?? 9:30 a.m.A  in Chinese (HK Time)







Conference code: 5951512#




Dial-in No.:A 







Mainland China Access Number:A 



4008 423 888 / 4006 786 286



Hong Kong Access Number:A 



+852 2112 1800



Taiwan Access Number:A 



+886 2 2162 6305



Singapore Access Number:A 



+65 6622 1171



Korea Access Number:A 



+82 2 3483 1261



Japan Access Number:



00 531 440 156



US Access Number:A 



+1 866 212 5567



UK Access Number:A 



+44 (0203) 024 5278



Germany Access Number:A 



+49 (69) 8092 1469



Denmark Access Number:A 



+45 (3) 272 7714



Brazil Access Number:A 



0800 892 3070



UAE Access Number:A 



8000 8520 9049



Montreal Access Number:A 



1 877 252 8508



Toronto Access Number:A 



+1 (647) 694 3021

About HMM0301
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2019    »
ПнВтСрЧтПтСбВс
 123
45678910
11121314151617
18192021222324
252627282930